Longitudinale Studie zu Lebensqualität und Versorgung bei Patienten mit Multipler Sklerose

John, Alison E.; Wienemann, G; Reese, J.; Wellek, Anne; Hagen, B; Dodel, R; Tackenberg, B.; Balzer‐Geldsetzer, Monika

doi:10.1055/s-0029-1238651

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is due to the fact that many patients do have difficulties getting and maintaining employment. In patients with multiple sclerosis, indirect costs are also very high (*4,500€/3 months) when comparing to a study of our group, the early onset of disabling diseases being the reason for high productivity losses [14]. Of note, in both studies we did not estimate the loss of productivity because of not finding a job, but only because of losing employment due to the disorder.…”

Section: Discussionmentioning

confidence: 60%

Cost of illness in patients with Gilles de la Tourette’s syndrome

et al. 2010

View full text Add to dashboard Cite

We evaluated the health economic burden of patients with Gilles de la Tourette's syndrome (GTS) in Germany over a 3-month observation period. Direct and indirect costs were evaluated in 200 outpatients with GTS (mean age 35 +/- 11.5 years) in Germany. Patients were recruited from three outpatient departments that specialized in GTS and completed a semi-structured and self-rating interview with questionnaires screening for direct and indirect medical and non-medical costs, health status, depression, amount and severity of symptoms. Costs were obtained from various German medical economic resources. Indirect costs for lost productivity were calculated using the human capital approach. Costs were calculated from the point of view of healthcare and transfer payment providers and the individual patient. Multivariate regression analyses were performed to identify independent cost predictors. Costs are in year 2006-2007 values. Direct costs were 620 +/- 1,697.1euro, including rehabilitation 98.8 +/- 993.6euro, hospitalization 195.8 +/- 1,267.8euro, outpatient treatment 14.0 +/- 40.6euro, ancillary treatment 51.9 +/- 137.4euro. Drug costs were 223.1 +/- 430.4. The indirect medical costs amounted to 2,511.3 +/- 3,809.5euro for productivity loss and to 220.0 +/- 1,092euro for absenteeism. The following variables were found to impact on direct costs: employment status, occupational advancement, depression, quality of life, age. Disease severity had no influence on cost. Because of the earlier age of disease onset, indirect costs are higher than direct costs. Interestingly, disease severity did not influence the resource need in this population. Unfortunately, no cost of illness studies are available for comparison. Further health economic studies, especially cost-effectiveness studies, are necessary for a basis for rational resource allocation.

show abstract

Section: Discussionmentioning

confidence: 60%